Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
Is Bosutinib a good option for a patient with E355G mutation with chronic myeloid leukemia?
Related Questions
How has your approach to utilizing MRD-guided therapy in previously untreated CLL changed since the FLAIR trial, particularly in choosing between continuous versus time-limited treatment?
Would you consider TKI discontinuation in a patient who has negative BCR transcripts on Bosutinib?
Would you re challenge a CLL patient, who had good response to Zanubrutinib but contracted cryptococcal pneumonia, with another TKI?
How should one approach an incidentally found T-cell gene arrangement?
Do you prefer to use 7+3 or CPX-351 as standard induction therapy in younger patients with AML-MRC or t-AML?
What is your approach to re-challenging BTK inhibitors for a patient who has had intolerance to several different agents?
Would concurrent CRLF2/IgH rearrangement affect your treatment recommendations for an adult patient with Ph+ p190 high risk (Age>35, WBC >30) B-cell ALL that was started on induction therapy with ponatinib + blinatumomab?
Is it possible to give Inotuzumab ozogamicin in the front line setting for an older patient with Ph- Pre-B-ALL?
Do you prefer quizartinib over midostaurin with chemotherapy induction for FLT3-ITD mutated AML given the results of QUANTUM-FIRST and preclinical advantages over other FLT3 inhibitors?
For AML patients, when do you stop antiinfective agents?
